• Mutation; HGNC; HGNC:4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=29100338; PubMed=32229503; PubMed=34732238).
  
• Mutation; HGNC; HGNC:9277; PPM1D; Simple; p.Cys478Ter (c.1434C>A); ClinVar=VCV001802564; Zygosity=Unspecified (PubMed=29100338; PubMed=32229503; PubMed=34732238).
  

PubMed=29100338; DOI=10.18632/oncotarget.19656; PMCID=PMC5652732
Xu C., Liu X.-Q., Geng Y.-B., Bai Q.-R., Pan C.-C., Sun Y., Chen X., Yu H., Wu Y.-L., Zhang P., Wu W.-H., Wang Y., Wu Z., Zhang J.-T., Wang Z.-H., Yang R., Lewis J., Bigner D.D., Zhao F.-P., He Y.-P., Yan H., Shen Q., Zhang L.-W.
Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors.
Oncotarget 8:76644-76655(2017)

PubMed=32229503; DOI=10.1158/1541-7786.MCR-19-0507
Wang Z.-H., Xu C., Diplas B.H., Moure C.J., Chen C.-P.J., Chen L.H., Du C.-Z., Zhu H.-S., Greer P.K., Zhang L.-W., He Y.-P., Waitkus M.S., Yan H.
Targeting mutant PPM1D sensitizes diffuse intrinsic pontine glioma cells to the PARP inhibitor olaparib.
Mol. Cancer Res. 18:968-980(2020)

PubMed=34732238; DOI=10.1186/s40478-021-01270-y; PMCID=PMC8565061
Xu C., Liu H., Pirozzi C.J., Chen L.H., Greer P.K., Diplas B.H., Zhang L.-W., Waitkus M.S., He Y.-P., Yan H.
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Acta Neuropathol. Commun. 9:178.1-178.12(2021)